Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A children's oncology group report

Clinical Cancer Research

Volumn 17, Issue 3, 2011, Pages 589-597

  Su, Jack M ^a   Li, Xiao Nan ^a   Thompson, Patrick ^a   Ou, Ching Nan ^b   Ingle, Ashish M ^c   Russell, Heidi ^a   Lau, Ching C ^a   Adamson, Peter C ^d   Blaney, Susan M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; VALPROIC ACID;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ANEMIA; ARTICLE; ASTROCYTOMA; ATYPICAL TERATOID RHABDOID TUMOR; BRAIN TUMOR; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPENDYMOMA; EWING SARCOMA; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HEADACHE; HEMATOTHORAX; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROBLASTOMA; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEIZURE; SOLID TUMOR; SOMNOLENCE; SPINDLE CELL SARCOMA; STEADY STATE; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLEEDING; VOMITING;

ACYLATION; ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; VALPROIC ACID; YOUNG ADULT;

EID: 79551691082     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0738     Document Type: Article

References (48)

1. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120. (Pubitemid 32662206)
2. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370(Pt 3):737-49. (Pubitemid 36399066)
3. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202. (Pubitemid 33741894)
4. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1497-511. (Pubitemid 41749195)
5. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
6. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)
7. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669-94. (Pubitemid 35176853)
8. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276:36734-41.
9. Gottlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78. (Pubitemid 34062289)
10. Knupfer MM, Pulzer F, Schindler I, Hernaiz Driever P, Knupfer H, Keller E. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 2001;21:347-51.
11. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63. (Pubitemid 38610247)
12. Erlich RB, Rickwood D, Coman WB, Saunders NA, Guminski A. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2008;63:381-9.
13. Cinatl J, Jr., Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996;7:766-73. (Pubitemid 26388767)
14. Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, et al. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res 2006;12: 4687-94. (Pubitemid 44297822)
15. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120:1787-94. (Pubitemid 46399367)
16. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58. (Pubitemid 43855268)
17. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64:1079-86. (Pubitemid 38176913)
18. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36. (Pubitemid 37163696)
19. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9.
20. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-8. (Pubitemid 47523148)
21. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-9. (Pubitemid 43032555)
22. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91. (Pubitemid 47477265)
23. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009;15:2479-87.
24. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-82. (Pubitemid 47057472)
25. Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-38. (Pubitemid 47365487)
26. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008;14:6296-301.
27. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009;100:28-36.
28. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005;4:22.
29. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009;15:2488-96.
30. Wolff JE, Kramm C, Kortmann RD, Pietsch T, Rutkowski S, Jorch N, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90:309-14.
31. Jolley ME. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol 1981;5:236-40. (Pubitemid 12242810)
32. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005;4:1912-22. (Pubitemid 43056974)
33. Hall K, Otten N, Irvine-Meek J, Leroux M, Budnick D, Verma M, et al. First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. Clin Pharmacokinet 1983;8:447-55. (Pubitemid 13009123)
34. Cloyd JC, Kriel RL, Fischer JH. Valproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy. Neurology 1985;35:1623-7.
35. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 1988;15:367-89.
36. Herngren L, Lundberg B, Nergardh A. Pharmacokinetics of total and free valproic acid during monotherapy in infants. J Neurol 1991; 238:315-9.
37. Herngren L, Nergardh A. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. J Neurol 1988;235:491-5. (Pubitemid 18262986)
38. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004;43:181. (Pubitemid 38891170)
39. Knupfer MM, Hernaiz-Driever P, Poppenborg H, Wolff JE, Cinatl J. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998;18: 3585-9. (Pubitemid 28546494)
40. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006;6:181.
41. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-85. (Pubitemid 46972780)
42. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002;40:789-801. (Pubitemid 35423414)
43. Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006;24:3678-85. (Pubitemid 46630544)
44. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85:159-70. (Pubitemid 47629397)
45. Ciusani E, Balzarotti M, Calatozzolo C, de Grazia U, Boiardi A, Salmaggi A, et al. Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 2007;16: 453-63.
46. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 2005;11:8467-75. (Pubitemid 41746962)
47. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005;114:380-6. (Pubitemid 40279957)
48. Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 2008;14:5410-5.